DOCSLIB.ORG

Special Edition: Chikungunya and Zika Virus October 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Europe’s journal on infectious disease epidemiology, prevention and control Special edition: Chikungunya and Zika virus October 2014 Featuring • Spread of chikungunya from the Caribbean to mainland Central and South America: a greater risk of spillover in Europe? • Aspects of Zika virus transmission • Cases of chikungunya virus infection in travellers returning to Spain from Haiti or Dominican Republic, April-June 2014 www.eurosurveillance.org Editorial team Editorial advisors Based at the European Centre for Albania: Alban Ylli, Tirana Disease Prevention and Control (ECDC), Austria: Reinhild Strauss, Vienna 171 83 Stockholm, Sweden Belgium: Koen De Schrijver, Antwerp Telephone number Belgium: Sophie Quoilin, Brussels +46 (0)8 58 60 11 38 Bosnia and Herzogovina: Nina Rodić Vukmir, Banja Luka E-mail Bulgaria: Mira Kojouharova, Sofia [email protected] Croatia: Sanja Musić Milanović, Zagreb Cyprus: to be nominated Editor-in-chief Czech Republic: Bohumir Križ, Prague Ines Steffens Denmark: Peter Henrik Andersen, Copenhagen Senior editor Estonia: Kuulo Kutsar, Tallinn Kathrin Hagmaier Finland: Outi Lyytikäinen, Helsinki France: Judith Benrekassa, Paris Scientific editors Germany: Jamela Seedat, Berlin Karen Wilson Greece: Rengina Vorou, Athens Williamina Wilson Hungary: Ágnes Csohán, Budapest Assistant editors Iceland: Haraldur Briem, Reykjavik Alina Buzdugan Ireland: Lelia Thornton, Dublin Ingela Söderlund Italy: Paola De Castro, Rome Associate editors Kosovo under UN Security Council Resolution 1244: Lul Raka, Pristina Andrea Ammon, Stockholm, Sweden Latvia: Jurijs Perevoščikovs, Riga Tommi Asikainen, Frankfurt, Germany Lithuania: Milda Zygutiene, Vilnius Mike Catchpole, London, United Kingdom Luxembourg: Thérèse Staub, Luxembourg Denis Coulombier, Stockholm, Sweden The former Yugoslav Republic of Macedonia: Elisaveta Stikova, Skopje Natasha Crowcroft, Toronto, Canada Malta: Tanya Melillo Fenech, Valletta Christian Drosten, Bonn, Germany Montenegro: Dragan Laušević, Podgorica Karl Ekdahl, Stockholm, Sweden Netherlands: Paul Bijkerk, Bilthoven Johan Giesecke, Stockholm, Sweden Norway: Hilde Klovstad, Oslo Herman Goossens, Antwerp, Belgium Poland: Malgorzata Sadkowska-Todys, Warsaw David Heymann, London, United Kingdom Portugal: Isabel Marinho Falcão, Lisbon Heath Kelly, Melbourne, Australia Romania: Daniela Pitigoi, Bucharest Irena Klavs, Ljubljana, Slovenia Serbia: Tatjana Pekmezovic, Belgrade Karl Kristinsson, Reykjavik, Iceland Slovakia: Lukáš Murajda, Martin Daniel Lévy-Bruhl, Paris, France Slovenia: Alenka Kraigher, Ljubljana Richard Pebody, London, United Kingdom Spain: Elena Rodríguez Valín, Madrid Panayotis T. Tassios, Athens, Greece Sweden: Christer Janson, Stockholm Hélène Therre, Paris, France Turkey: Fehmaniz Temel, Ankara Henriette de Valk, Paris, France United Kingdom: Norman MacDonald, Glasgow Sylvie van der Werf, Paris, France European Commission: Paolo Guglielmetti, Luxembourg World Health Organization Regional Office for Europe: Nedret Design / Layout Emiroglu, Copenhagen Fabrice Donguy / Arne Haeger Online submission system http://www.editorialmanager.com/eurosurveillance/ www.eurosurveillance.org © Eurosurveillance, 2014 Contents Chikungunya and Zika Zika Editorial Rapid communications Integrated surveillance for prevention and control Two cases of Zika fever imported from French of emerging vector-borne diseases in Europe 2 Polynesia to Japan, December 2013 to January 2014 50 JC Semenza et al. S Kutsuna et al. First case of laboratory-confirmed Zika virus Chikungunya infection imported into Europe, November 2013 54 D Tappe et al. Editorials Zika virus infection complicated by Guillain-Barré Spread of chikungunya from the Caribbean to syndrome – case report, French Polynesia, mainland Central and South America: a greater risk December 2013 58 of spillover in Europe? 6 E Oehler et al. H Noël et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 Rapid communications and February 2014 61 M Besnard et al. Dengue virus serotype 4 and chikungunya virus coinfection in a traveller returning from Luanda, Potential for Zika virus transmission through blood Angola, January 2014 9 transfusion demonstrated during an outbreak in R Parreira et al. French Polynesia, November 2013 to February 2014 65 Emergence of chikungunya fever on the French side D Musso et al. of Saint Martin island, October to December 2013 13 S Cassadou et al. Importance of case definition to monitor ongoing outbreak of chikungunya virus on a background of actively circulating dengue virus, St Martin, December 2013 to January 2014 17 R Omarjee et al. Cases of chikungunya virus infection in travellers returning to Spain from Haiti or Dominican Republic, April-June 2014 20 A Requena-Méndez et al. Large number of imported chikungunya cases in mainland France, 2014: a challenge for surveillance and response 25 MC Paty et al. Euroroundups Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe 30 W Van Bortel et al. Research article Local and regional spread of chikungunya fever in the Americas 41 S Cauchemez et al. © Eurosurveillance Illustration of mosquito, map of outbreak www.eurosurveillance.org 1 Editorials Integrated surveillance for prevention and control of emerging vector-borne diseases in Europe J C Semenza ([email protected])1, H Zeller1 1. European Centre for Disease Prevention and Control, Stockholm, Sweden Citation style for this article: Semenza JC, Zeller H. Integrated surveillance for prevention and control of emerging vector-borne diseases in Europe. Euro Surveill. 2014;19(13):pii=20757. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20757 Article submitted on 28 March 2014 / published on 3 April 2014 World Health Day, celebrated on 7 April, marks the spots’ of emerging infectious diseases [12]. A case- anniversary of the founding of the World Health in-point is the importation, establishment and expan- Organization (WHO) in 1948. This year, vector-borne sion of the Asian tiger mosquito (Aedes albopictus), diseases which are transmitted mainly by bites of first recorded in Albania in the 1970s and subsequently vectors such as mosquitoes, ticks and sandflies are in Italy in the 1990s. The mosquito was imported in highlighted as a global public health priority. This used car tires from the United States into Genova and issue of Eurosurveillance focuses on vector-borne dis- Venice, both in Italy, from where the mosquito spread eases and their impact on public health in Europe and [13]. Dedicated vector surveillance activities (Figure 1) other parts of the world such as the recent outbreaks have documented that the vector has expanded due to of Chikungunya fever in the Caribbean and Zika virus permissive climatic and environmental conditions and fever in the Pacific [1-6]. is now established in numerous regions in Europe. Mosquito-borne diseases Dengue and malaria are important mosquito-borne Astute surveillance activities were able to detect the viral diseases, often also referred to as ‘tropical’ dis- autochthonous transmission of Chikungunya and den- eases. Globally, dengue is the most common mosquito- gue viruses by Ae. albopictus in Europe triggered by borne viral disease, with an estimated 390 million infected travellers returning from endemic areas [13, infections per year and 40% of the world’s population 14]. Through vector surveillance, Ae. aegypti mosqui- at risk [7]. While interventions to control mosquitoes toes, the main vectors of dengue, were first detected have resulted in a decrease of malaria cases, WHO in Madeira, Portugal in 2005 where they dispersed nonetheless estimates that 219 million individuals across the southern coastal areas of the island. From were infected in 2010, of which 660,000 died, predomi- September 2012 to January 2013, the island experi- nantly in Africa [8]. enced a large dengue outbreak, affecting more than 2,100 individuals, including 78 cases exported to con- Yet, vector-borne diseases are also a threat to public tinental Europe; the responsible dengue virus serotype health in Europe. Mounting an effective public health DEN-1 was traced back to a probable Central or South response can counteract challenges posed by them American origin [15]. and protect humans from infections; dedicated activi- ties such as disease and vector surveillance as well as In December 2013, public health surveillance confirmed monitoring infectious disease drivers (e.g. environmen- the first local transmission of Chikungunya virus in the tal or climatic conditions) can help to anticipate and to Caribbean. Within three months the virus spread from respond to emerging vector-borne diseases [9, 10]. Saint Martin island to six other neighbouring islands and autochthonous transmission was even reported Globalisation and environmental change; social and in French Guiana, South America. Cassadou et al. and demographic change; and health system capacity are Omarjee et al. in this issue describe the importance of three interacting drivers that can set the stage for proactive public health practice during such a vector- novel vector-borne disease scenarios [11]. The chang- borne disease emergence [1]. Chikungunya infections ing dynamic of these drivers can potentially create new were identified in a cluster of patients suffering from constellations of threats that challenge control meas- a febrile dengue-like illness with severe joint pain and ures. Pathogens and vectors are bound to disseminate
Recommended publications
  • Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses

    Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses

    ARIZONA ARBOVIRAL HANDBOOK FOR CHIKUNGUNYA, DENGUE, AND ZIKA VIRUSES 7/31/2017 Arizona Department of Health Services | P a g e 1 Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses OBJECTIVES .............................................................................................................. 4 I: CHIKUNGUNYA ..................................................................................................... 5 Chikungunya Ecology and Transmission ....................................... 6 Chikungunya Clinical Disease and Case Management ............... 7 Chikungunya Laboratory Testing .................................................. 8 Chikungunya Case Definitions ...................................................... 9 Chikungunya Case Classification Algorithm ............................... 11 II: DENGUE .............................................................................................................. 12 Dengue Ecology and Transmission .............................................. 14 Dengue Clinical Disease and Case Management ...................... 14 Dengue Laboratory Testing ......................................................... 17 Dengue Case Definitions ............................................................ 19 Dengue Case Classification Algorithm ....................................... 23 III: ZIKA ..................................................................................................................
  • WORLD HEALTH DAY Monday 7THAPRIL 2014 "VECTOR BORNE DISEASES"

    WORLD HEALTH DAY Monday 7THAPRIL 2014 "VECTOR BORNE DISEASES"

    WORLD HEALTH DAY Monday 7THAPRIL 2014 "VECTOR BORNE DISEASES" Dr Raman Velayudhan Coordinator Vector Ecology and Management Dept. of Control of NTD World Health Day (WHD) What is WHD? World Health Day is celebrated on 7 April every year to mark the anniversary of the founding of WHO in 1948. Each year a theme is selected that highlights a priority area of public health. It is a flagship campaign of the Director General. Activities are planned in all regional offices and country offices (working closely with the ministry of Health) Regional offices and countries can have their on priority under the theme. WHD –past themes 2013 - Silent killer – control your blood pressure 2012 - Good health adds life to years 2011 – Anti-microbial Resistance 2010 – Urbanization and health 2009 – Make hospitals safe in emergencies 2008 – Protecting health from climate change 2007 – International Health security 2006 – Working together for health 2005 – Making every mother and child count GOAL The campaign aims to raise awareness about the threat posed by vectors and vector-borne diseases and to stimulate families and communities to take action to protect themselves. As vector-borne diseases begin to spread beyond their traditional boundaries, cross - border action needs to be taken where these diseases currently thrive. Specific objectives families know how to protect themselves; travelers know how to protect themselves when travelling to countries where these pose a health threat; in countries where vector-borne diseases are a public health problem, ministries of health put in place measures to improve the protection of their populations; and in countries where vector-borne diseases are an emerging threat, health authorities work with environmental and relevant authorities locally and in neighboring countries to improve integrated surveillance of vectors and to take measures to prevent their proliferation.
  • Zika Virus Outside Africa Edward B

    Zika Virus Outside Africa Edward B

    Zika Virus Outside Africa Edward B. Hayes Zika virus (ZIKV) is a flavivirus related to yellow fever, est (4). Serologic studies indicated that humans could also dengue, West Nile, and Japanese encephalitis viruses. In be infected (5). Transmission of ZIKV by artificially fed 2007 ZIKV caused an outbreak of relatively mild disease Ae. aegypti mosquitoes to mice and a monkey in a labora- characterized by rash, arthralgia, and conjunctivitis on Yap tory was reported in 1956 (6). Island in the southwestern Pacific Ocean. This was the first ZIKV was isolated from humans in Nigeria during time that ZIKV was detected outside of Africa and Asia. The studies conducted in 1968 and during 1971–1975; in 1 history, transmission dynamics, virology, and clinical mani- festations of ZIKV disease are discussed, along with the study, 40% of the persons tested had neutralizing antibody possibility for diagnostic confusion between ZIKV illness to ZIKV (7–9). Human isolates were obtained from febrile and dengue. The emergence of ZIKV outside of its previ- children 10 months, 2 years (2 cases), and 3 years of age, ously known geographic range should prompt awareness of all without other clinical details described, and from a 10 the potential for ZIKV to spread to other Pacific islands and year-old boy with fever, headache, and body pains (7,8). the Americas. From 1951 through 1981, serologic evidence of human ZIKV infection was reported from other African coun- tries such as Uganda, Tanzania, Egypt, Central African n April 2007, an outbreak of illness characterized by rash, Republic, Sierra Leone (10), and Gabon, and in parts of arthralgia, and conjunctivitis was reported on Yap Island I Asia including India, Malaysia, the Philippines, Thailand, in the Federated States of Micronesia.
  • To Build a Fairer, Healthier World for Everyone, Everywhere

    To Build a Fairer, Healthier World for Everyone, Everywhere

    It’s time to build a fairer, healthier world for everyone, everywhere. World Health Day 2021 Health equity and its determinants Health equity and its Health inequity and COVID-19 determinants Around the globe, COVID-19 has run along the seams of existing health inequities – the unfair This is the second World Health Day to and preventable differences in people’s health, fall during the COVID-19 pandemic – well-being, and access to quality health services. the world’s worst peacetime health crisis This is shown by the fact that COVID-19 cases and deaths in deprived areas are double those of in a century. It comes amidst gruelling more advantaged areas. and painful times for the world’s people who are dealing with the impacts of the Health inequity manifests itself in our pandemic, including those working in the communities: people worst affected by health sector. COVID-19 are those least able to withstand it – older people and others with pre-existing severe illness; socially disadvantaged people As of 1 April 2021, over 2.8 million people had with serious health conditions such as heart died from the COVID-19 virus, and more than disease and diabetes; people without Internet 130 million people had contracted it – many of access unable to receive the latest information whom now live with long-term health impacts. At to protect themselves; people unable to afford the same time, the wider health consequences out-of-pocket payments for treatment; and those of the pandemic have left untold millions bearing socially excluded, for example homeless people, the costs in terms of their emotional, social, or migrants, who may also experience obstacles and economic well-being.
  • Overview of Zika

    Overview of Zika

    Overview of Zika Alan D.T. Barrett Department of Pathology Sealy Center for Vaccine Development University of Texas Medical Branch Galveston TX Disclaimer • Over 700 papers in pubmed on Zika in the last 12 months. • Impossible to stay up to date as field is moving so fast. • Only including material in public domain. ZIKV: 1947-2006 • Zika virus (ZIKV) causes Zika fever (ZF), an acute febrile illness characterized by a rash, conjunctival injection, arthralgia, myalgia and headache. • The disease appears in all age groups with an incubation period on the order of 3-14 days and a symptomatic phase lasting about 2-7 days. • Treatment is largely symptomatic. • The illness is mild in nature with a very low rate of hospitalization. • The vast majority of patients make a full recovery and while death is rarely reported, it has primarily occurred in the immunocompromised or those with other complicating medical conditions. • Only 14 clinical cases in the literature from 1951-2006. Map showing the known distribution of Zika virus based on serosurveys, virus detection, and laboratory-diagnosed cases. Blue arrows show recent patterns of spread deduced from phylogenetic studies Weaver et al Antiviral Research, Volume 130, 2016, 69–80 ZIKV in the Americas Current ZIKV activity ZIKV transmission • ZIKV is primarily transmitted by Aedes spp. Mosquitoes. • Infectious ZIKV particles have been demonstrated in urine, saliva, semen, blood products, and breast milk possible vehicles of transmission. • Male-to-female and male-to-male transmission of ZIKV have been reported, but only from individuals with clinical signs/symptoms of ZIKV infection. • Establishing person-to-person transmission is difficult, as contacts frequently have the same environmental exposures.
  • Boarding Pass

    Boarding Pass

    BOARDING PASS TRAVELER/CARIBBEAN SMALL BITE, BIG THREAT VECTOR-BORNE DISEASES: KNOW BEFORE YOU TRAVEL TAKE SIMPLE STEPS TO PROTECT YOURSELF AND YOUR FAMILY VECTORS CAUSE DISEASE Like the yellow fever Serious diseases such Watch for symptoms mosquito & Asian tiger as: including: SEE REVERSE 1A mosquito o Fever o Dengue o Joint pain or swelling GATE A 37 o Chikungunya o Severe headache, SEAT 15 E (chik-un-gun-ya) muscle pain, or rash ZONE 2 WORLD TRAVELER Non-smoking Find travel notices, destination information, and travel clinic info at www.cdc.gov/travel flight TRAVEL ADVICE TAKE SIMPLE MEASURES TO PROTECT YOURSELF AND YOUR FAMILY If you are unable to protect yourself Use insect repellents on from mosquitoes inside your hotel, skin and/or clothing sleep under an mosquito bed net No vaccines exist to prevent Chikungunya or Dengue, but getting recommended travel vaccinations for your destination is always an Contact your healthcare provider or important step for trip planning nearest travel clinic for advice about travelers health prior to traveling. Help reduce the number of mosquitoes If you suspect symptoms of Use air conditioning or outside your hotel room by emptying window/door screens to Chikungunya or Dengue during or after standing water from containers such as keep mosquitoes outside travel, immediately contact your flowerpots or buckets healthcare provider or local medical care facility and avoid mosquito bites. Adapted from World Health Organization World Health Day Boarding Pass http://www.who.int/campaigns/world-health-day/2014/en/ .
  • Media Fact Sheet Antimicrobial Resistance: No Action Today, No Cure Tomorrow

    Media Fact Sheet Antimicrobial Resistance: No Action Today, No Cure Tomorrow

    World Health Day: Media Fact Sheet Antimicrobial resistance: no action today, no cure tomorrow Antimicrobial resistance - when germs change in a way that reduces or eliminates the effectiveness of drugs to treat them - is a growing global problem. Antimicrobial treatments, which include antibiotics, antivirals, antifungals, and other medications, are some of the most important tools we have to combat life‐threatening diseases. Inappropriate antimicrobial use drives resistance – harms patients On this page: Antimicrobial use in U.S. All use of antimicrobials in inpatient and healthcare settings outpatient settings drives antibiotic resistance Antiviral resistance and HIV and increases one’s chance of acquiring an Antiviral resistance and influenza antimicrobial-resistant infection. Therefore, it is Antimicrobial resistance and important to use antibiotics only when needed. malaria Antimicrobial or drug resistance is compromising Antimicrobial resistance and the effectiveness of these important treatments Neisseria gonorrhoeae and increases the patient’s risk of complications Antimicrobial resistance and or death. Patients, healthcare providers, tuberculosis (TB) hospital administrators, industry, and policy makers must work together to employ effective strategies for improving antimicrobial use – ultimately saving lives. Antimicrobial resistance in U.S. healthcare and community settings Scope of the problem: It is estimated that approximately 50% of antimicrobials, particularly antibiotics, are unnecessarily or inappropriately prescribed
  • Zika Virus E an Overview

    Zika Virus E an Overview

    + MODEL Microbes and Infection xx (2016) 1e7 www.elsevier.com/locate/micinf Review Zika virus e an overview Camila Zanluca, Claudia Nunes Duarte dos Santos* Laboratorio de Virologia Molecular, Instituto Carlos Chagas, Fundaçao~ Oswaldo Cruz, Curitiba, PR, Brazil Received 14 February 2016; accepted 3 March 2016 Available online ▪▪▪ Abstract Zika virus (ZIKV) is currently one of the most important emerging viruses in the world. Recently, it has caused outbreaks and epidemics, and has been associated with severe clinical manifestations and congenital malformations. However to date, little is known about the pathogenicity of the virus and the consequences of ZIKV infection. In this paper, we provide an overview of the current knowledge on ZIKV. © 2016 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. Keywords: Zika virus; Flavivirus; Arthropod-borne virus; Viral emergence 1. Introduction 2. Epidemiology Zika virus (ZIKV) is an arthropod-born virus (arbovirus) Zika virus was first isolated in 1947 from the serum of a belonging to the genus Flavivirus and the family Flaviviridae sentinel Rhesus monkey from the Zika Forest (Uganda) during [1]. The virus carries the name of the forest where it was first a study on the transmission of yellow fever. The second identified [2], a name that means “overgrown” in the Luganda isolation was made from a pool of Aedes (Stegomyia) africa- language [3]. nus mosquitoes from the same forest in 1948 [2]. The occur- Beyond ZIKV, the genus Flavivirus comprises 52 other rence of human infection was first evidenced by the presence viral species, including the dengue, yellow fever, Saint Louis of neutralising antibodies in the sera of east African residents encephalitis and West Nile viruses [1].
  • World Health Day April 7, 2021 As the Work Programme Under Eu4health Is Developed, EFPA Calls For

    World Health Day April 7, 2021 As the Work Programme Under Eu4health Is Developed, EFPA Calls For

    World Health Day April 7, 2021 As the work programme under EU4Health is developed, EFPA calls for: EFPA calls on the EU to make Recognition of the need to fund programmes ‘EU4Health count 4 Mental Health 2’ improving the mental health needs of the citizens especially but not solely to respond to In coming together to celebrate this year’s World the long-term implications of Covid-19. Health Day, the European Federation of Research is needed but the needs are likely to be Psychologists’ Associations (EFPA) welcomes the greater among the young and people of working (1) European Commission announcement on 26 age. March that the €5.1bn EU4Health programme is coming into force. A focus on prevention in “building a fairer, EFPA particularly welcomes the focus on healthier world” (5) which is in line with the 10th improving and fostering health, enhancing UN Sustainable Development goal of reducing accessibility of healthcare, and strengthening inequalities (6). Tackling these societal challenges healthcare systems. requires a focus on the impact of social and behavioural determinants of health.(7) Such The proposed areas of action and health determinants as lack of healthcare access, risky (2) priorities including pandemic preparedness behaviour and poor working conditions are and transformation of accessibility of healthcare factors identified across Europe as having a clear systems are undeniably essential. Mental well- impact on physical and mental health. (8) being of the citizens of Europe however must not be forgotten. As the World Health Organisation A shift in the education and training of (3), Regional Office for Europe has made clear professionals.
  • Dengue Fever/Severe Dengue Fever/Chikungunya Fever! Report on Suspicion of Infection During Business Hours

    Dengue Fever/Severe Dengue Fever/Chikungunya Fever! Report on Suspicion of Infection During Business Hours

    Dengue Fever/Severe Dengue Fever/Chikungunya Fever! Report on suspicion of infection during business hours PROTOCOL CHECKLIST Enter available information into Merlin upon receipt of initial report Review background information on the disease (see Section 2), case definitions (see Section 3 for dengue and for chikungunya), and laboratory testing (see Section 4) Forward specimens to the Florida Department of Health (DOH) Bureau of Public Health Laboratories (BPHL) for confirmatory laboratory testing (as needed) Inform local mosquito control personnel of suspected chikungunya or dengue case as soon as possible (if applicable) Inform state Arbovirus Surveillance Coordinator on suspicion of locally acquired arbovirus infection Contact provider (see Section 5A) Interview case-patient Review disease facts (see Section 2) Mode of transmission Ask about exposure to relevant risk factors (see Section 5. Case Investigation) History of travel, outdoor activities, and mosquito bites two weeks prior to onset History of febrile illness or travel for household members or other close contacts in the month prior to onset History of previous arbovirus infection or vaccination (yellow fever, Japanese encephalitis) Provide education on transmission and prevention (see Section 6) Awareness of mosquito-borne diseases Drain standing water at least weekly to stop mosquitoes from multiplying Discard items that collect water and are not being used Cover skin with clothing or Environmental Protection Agency (EPA)-registered repellent such as DEET (N,N-diethyl-meta-toluamide) Use permethrin on clothing (not skin) according to manufacturer’s directions Cover doors and windows with intact screens to keep mosquitoes out of the house Enter additional data obtained from interview into Merlin (see Section 5D) Arrange for a convalescent specimen to be taken (if necessary) Dengue/Chikungunya Guide to Surveillance and Investigation Dengue Fever/Severe Dengue/Chikungunya 1.
  • World Health Day 2018

    World Health Day 2018

    World Health Day 2018 Campaign Essentials “Health is a human right. No one should get sick or die just because they cannot access the services they need.” – Dr Tedros Adhanom Ghebreyesus Introduction The World Health Organization was founded on the principle that all people should be able to realize their right to the highest possible level of health. Its Constitution came into force on 7 April 1948. “#HealthForAll” has therefore been WHO’s guiding vision for more than seven decades. It’s also the impetus behind the current organization-wide drive to support countries in moving towards Universal Health Coverage (UHC). Experience has illustrated, time and again, that Universal Health Coverage is achieved when political will is strong. So in this 70th anniversary year, WHO is calling on world leaders to live up to the pledges they made when they agreed the Sustainable Development Goals in 2015, and commit to concrete steps to advance the health of all people. This means ensuring that everyone, everywhere, receive the health services they need without facing financial hardship. The Organization will maintain a high-profile focus on universal health coverage via a series of events through 2018, starting on World Health Day on 7 April with global and local conversations about ways to achieve #HealthForAll.” Why universal health coverage matters? Countries that invest in universal health coverage make a sound investment in their human capital. In recent decades, universal health coverage has emerged as a key strategy to make progress towards other health-related and broader development goals. Access to essential quality care and financial protection not only enhances people’s health and life expectancy, it also protects countries from epidemics, reduces poverty and the risk of hunger, creates jobs, drives economic growth, and enhances gender equality.
  • Supplementary File 1: Searching Supplements (Snowballing Sources, Completed Database Searches, Data Base Results)

    Supplementary File 1: Searching Supplements (Snowballing Sources, Completed Database Searches, Data Base Results)

    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplementary File 1: Searching Supplements (snowballing sources, completed database searches, data base results) Table 1: Snowballing source and number of returns Email list Contact Team member No. of resources CH-CoP SB/AT 5 CORE Group SB 2 Collectivity / FARAFRA AT 0 CHW-TWG SB 0 UNICEF SB 1 USAID SB 0 Websites Websites Team Member No. of resources World Health Organization Covid-19 database VdC 18 Centre for Disease Control (Atlanta) AT 10 Centre for Disease Control (Africa) AT 0 https://www.nccmt.ca/knowledge-repositories/covid-19- evidence-reviews AT 5 https://www.evidenceaid.org/coronavirus-covid-19-evidence- collection/ AT 0 https://www.cochrane.org/coronavirus-covid-19-cochrane- resources-and-news VdC 0 http://blogs.lshtm.ac.uk/hppdebated/2020/04/08/evidence-to- inform-the-covid-19-response-collection-of-hpp-papers/ SB 6 https://www.ids.ac.uk/publications/covid-19-health-evidence- summaries/?utm_campaign=News%20at%20IDS%208%20April% 202020&utm_source=emailCampaign&utm_content=&utm_me dium=email SB 0 Mesh Community Engagement Network SB 0 British Red Cross Community Engagement Hub VdC 2 Covid-19 Research Knowledge Hub VdC ReliefWeb AT 3 WHO Website VdC 6 Google Search - first 10 pages of "community engagement + (Zika, Sars, etc) SB 12 John Hopkins University (https://www.mcsprogram.org/resource-search- results/?_sf_s=Zika) 2 Total: 64 Duplicates: 29 Taken to Full text screen: 35 Gilmore B, et al.